| AbbVie Commits $750M to Genmab Bispecific Antibody Cancer Drug Deal | Sarah de Crescenzo | 06/10/20 | National |
| Atlas Venture Raises $400M Fund to Seed Another New Set of Biotechs | Sarah de Crescenzo | 06/05/20 | Boston |
| Pliant Therapeutics Prices IPO, Lands $144M to Test Fibrosis Drugs | Frank Vinluan | 06/03/20 | San Francisco |
| Chinook, Aduro Merger Plan Sets Up New Kidney Disease-Focused Biotech | Frank Vinluan | 06/02/20 | Seattle |
| Forma Therapeutics Eyes IPO to Advance Sickle Cell, Prostate Cancer Drugs | Sarah de Crescenzo | 05/29/20 | Boston |
| Bio Roundup: FDA Dings BMS, Genfit’s Fall, Alexion’s Activist & More | Sarah de Crescenzo | 05/15/20 | National |
| BCMA Delay: FDA Refuses Review of Bristol Drug, Asks for More Info | Frank Vinluan | 05/13/20 | New York |
| Pliant Pushes Forward With IPO Plans to Back Fibrosis Drug Studies | Frank Vinluan | 05/12/20 | San Francisco |
| Eli Lilly Gets Edge in the “RET” Race With FDA Nod for Cancer Drug | Frank Vinluan | 05/08/20 | Indiana |
| Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More | Frank Vinluan | 05/08/20 | National |
| Ayala’s IPO Raises $55M to Test Two Former Bristol Myers Cancer Drugs | Frank Vinluan | 05/08/20 | National |
| Novartis Drug Wins FDA Approval for Lung Cancers With Specific Mutation | Frank Vinluan | 05/06/20 | National |
| Ventus Launches With $60M to Shine Light on Innate Immune System Drugs | Frank Vinluan | 05/06/20 | Boston |
| Adicet Aims to Advance CAR-T Therapies in Reverse Merger with resTORbio | Sarah de Crescenzo | 04/29/20 | Boston |
| Taysha Launches With $30M to Bring Gene Therapy to CNS Disorders | Frank Vinluan | 04/29/20 | Texas |
| Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More | Frank Vinluan | 04/24/20 | National |
| FDA Approves Incyte Drug, First Ever for Rare Bile Duct Cancer | Frank Vinluan | 04/20/20 | National |
| Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More | Sarah de Crescenzo | 04/17/20 | National |
| UroGen Gets FDA Nod for Low-Grade Upper Tract Urothelial Cancer Drug | Sarah de Crescenzo | 04/15/20 | New York |
| Blackstone Pays Alnylam $1B to Grab a Stake in RNAi Drug Inclisiran | Frank Vinluan | 04/13/20 | Boston |
| Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More | Sarah de Crescenzo | 04/03/20 | National |
| A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy | Frank Vinluan | 03/31/20 | Raleigh Durham |
| FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch | Frank Vinluan | 03/26/20 | New York |
| Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing | Brenda Sandburg | 03/24/20 | National |
| Kala to Take Another Shot at FDA Approval With New Dry Eye Drug Data | Sarah de Crescenzo | 03/09/20 | Boston |
| Cushing’s Disease Drug That Novartis Sold to Recordati Nabs FDA Nod | Frank Vinluan | 03/09/20 | Europe |
| Zentalis Leads a Trio of Biotechs Charting a Course for Wall Street | Frank Vinluan | 03/09/20 | New York |
| Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More | Sarah de Crescenzo | 03/06/20 | National |
| Novartis Leads $100M Round for Fibrosis-Focused Pliant Therapeutics | Frank Vinluan | 03/03/20 | San Francisco |
| Esperion’s FDA-Approved Cholesterol Drug Priced Even Lower Than Expected | Frank Vinluan | 02/24/20 | Detroit Ann Arbor |
